Clinical Trial Update: Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of docetaxel (Taxotere), cisplatin, and irinotecan (CPT-11) for esophagogastric cancers has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Camptosar (irinotecan)
• Taxotere (docetaxel)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Esophageal Cancer, Gastric Cancer | Phase 2 | Status: COMPLETED